

# Resource Summary Report

Generated by [RRID](#) on Sep 10, 2026

## Spotfire

RRID:SCR\_008858

Type: Tool

---

### Proper Citation

Spotfire (RRID:SCR\_008858)

---

### Resource Information

**URL:** <http://spotfire.tibco.com/>

**Proper Citation:** Spotfire (RRID:SCR\_008858)

**Description:** The Spotfire Gene Ontology Advantage Application integrates GO annotations with gene expression analysis in Spotfire DecisionSite for Functional Genomics. Researchers can select a subset of genes in DecisionSite visualizations and display their distribution in the Gene Ontology hierarchy. Similarly, selection of any process, function or cellular location in the Gene Ontology hierarchy automatically marks the corresponding genes in DecisionSite visualizations. Platform: Windows compatible

**Abbreviations:** Spotfire

**Synonyms:** Tibco Spotfire, Spotfire Inc., Spotfire Gene Ontology Advantage Application, Spotfire - TIBCO Software

**Resource Type:** software resource

**Keywords:** analysis, predictive analytics, big data, visualization, gene ontology, annotation, gene expression, functional genomics, gene, function, cellular location, statistical analysis, genomics

**Availability:** Commercial license. Spotfire is available for purchase (individual license / enterprise use) / Free trial.

**Resource Name:** Spotfire

**Resource ID:** SCR\_008858

**Alternate IDs:** nlx\_149169

**Record Creation Time:** 20220129T080249+0000

**Record Last Update:** 20260905T132629+0000

---

## Ratings and Alerts

No rating or validation information has been found for Spotfire.

No alerts have been found for Spotfire.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 490 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Li Z, et al. (2026) Adaptive evolution of gene regulatory networks in mammalian neocortex. *Nature*, 653(8113), 156.

Collotta G, et al. (2026) USP7 deubiquitinase stabilizes FAN1 to support DNA crosslink repair and suppress CAG repeat expansion. *Nature communications*, 17(1).

Russo MR, et al. (2026) Protocol for cell cycle-resolved high-content imaging of transcription condensate dynamics in human cells. *STAR protocols*, 7(2), 104589.

Orsini Delgado ML, et al. (2026) EB1010, a putative Christensenellaceae-derived microbial peptide, exhibits anti-inflammatory activity and therapeutic potential in ulcerative colitis. *Gut microbes*, 18(1), 2662547.

Roberts I, et al. (2026) Bioinformatic assessment of the potential amyloidogenicity of the human and evolutionarily more ancient proteomes. *The Biochemical journal*, 483(8), 1337.

Bigaud B, et al. (2026) Impact of multiplex PCR point-of-care platform implementation for respiratory pathogen detection in an emergency department with high daily patient volume. *Journal of clinical microbiology*, 64(1), e0131325.

Uruci S, et al. (2026) CFAP20 salvages arrested RNAPII from the path of co-directional replisomes. *Nature*, 650(8103), 1025.

Takahashi K, et al. (2026) Immunological profile of the tumor immune microenvironment of upper tract urothelial carcinoma predicts recurrence patterns. *Cancer immunology, immunotherapy : CII*, 75(2), 41.

Favuzza P, et al. (2026) MK-7602: a potent multi-stage dual-targeting antimalarial. *EBioMedicine*, 123, 106061.

Perez RK, et al. (2026) TET1 deficiency amplifies macrophage inflammatory signaling associated with Crohn's disease. *Inflammation research : official journal of the European Histamine Research Society ... [et al.]*, 75(1).

Fenoglio S, et al. (2026) Temporal control of sgRNA library activation unlocks large-scale in vivo CRISPR screens. *Cell reports methods*, 6(7), 101470.

Kafka E, et al. (2026) TCA cycle rewiring underpins histone acetylation sourcing and cell-fate transitions during exit from naive pluripotency. *Cell stem cell*, 33(5), 820.

Sato F, et al. (2025) Diverse Effects of Various Toll-Like Receptor 2 Ligands on Neuronal Activity and Cell Death. *Cellular and molecular neurobiology*, 46(1), 4.

van Pamel J, et al. (2025) The gut-brain-axis one year after treatment with cladribine tablets in patients with relapsing remitting multiple sclerosis: a pilot study. *Frontiers in immunology*, 16, 1514762.

Ito Y, et al. (2025) Feasibility of Intratumoral Administration With EPHB4-CAR-T Cells for the Treatment of Oral Squamous Cell Carcinoma. *Cancer science*, 116(5), 1227.

Chen Z, et al. (2025) Development of PVTX-405 as a potent and highly selective molecular glue degrader of IKZF2 for cancer immunotherapy. *Nature communications*, 16(1), 4095.

Scarpellini C, et al. (2025) Oxazole-Based Ferroptosis Inhibitors with Promising Properties to Treat Central Nervous System Diseases. *Journal of medicinal chemistry*, 68(4), 4908.

Bando H, et al. (2025) Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma - a multicenter phase 2 trial (EPOC1802). *Nature cancer*, 6(3), 445.

Li D, et al. (2025) Quantitative hypermorphic FAM111A alleles cause autosomal recessive Kenny-Caffey syndrome type 2 and osteocraniostenosis. *JCI insight*, 10(6).

Arsiwala A, et al. (2025) A high-throughput platform for biophysical antibody developability assessment to enable AI/ML model training. *mAbs*, 17(1), 2593055.